Therapeutic advances in hepatocellular carcinoma;Avancées thérapeutiques dans le carcinome hepatocellular

Bulletin de l'Academie Nationale de Medecine

Volumn 192, Issue 1, 2008, Pages 23-32

  Poupon, Raoul ^a   Fartoux, Laetitia ^a   Rosmorduc, Olivier ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Chemoembolization; Drug therapy; Hepatocellular carcinoma; Liver; Liver transplantation; Radiotherapy; Surgery; Therapeutic

Indexed keywords

HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVER TUMOR; PALLIATIVE THERAPY; REVIEW;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PALLIATIVE CARE;

EID: 54049084681     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)32864-x     Document Type: Article

References (24)

1. PARKIN DM, BRAY F, FERLAY J, PISANI P. - Global cancer statistics. CA Cancer J. Clin. 2005, 55, 74-108.
2. REMONTET L, BOUVIER J, BOUVIER AM et al. - Cancer incidence and mortality in France over the period 1978-200. Rev. Epidemiol. Sante Publique 2003, 51, 3-30.
3. Hepatocellular carcinoma. Screening, diagnosis and mamagement. Gastroenterology 2004, 127, Suppl 1, S1-S323.
4. BOLONDI L. - Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003, 39, 1076-1084.
5. BRUIX J, SHERMAN M. - Practice guidelines committee, American for the Study of the Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005, 42, 1208-1236.
6. [6] LIBRAGHI T, GOLDBERG SN, LAZZARONI S, MELONI F, SOLBIATI L et al. - Small hepatocellular carcinoma : treatment with radio-frequency ablation versus ethanol injection. Radiology 1999, 210, 655-661. (Pubitemid 29124024)
7. [7] LLOVET JM, BREUIX J. - Systematic review of randomized trials for unresectable hepatocellu-lar carcinoma : chemoembolization improves survival. Hepatology 2003, 37, 429-442 (Pubitemid 36152543)
8. [8] CAMMA C, SCHEPIS F, ORLANDO A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma : meta-analysis of randomized controlled trials. Radiology 2002, 224, 47-54. (Pubitemid 34680374)
9. [9] HONG K, KOBEITER H, GEORGIADES CS, TORBENSON M, GESCHWIND JFH.-Effects of the type of embolization particles on carboplatin concentration in liver tumors after transcatheter arterial chemoembolization in a rabbit model of liver cancer. J Vasc Interv Radiol 2005, 16, 1711-1717. (Pubitemid 44431170)
10. [10] VARELA M., REAL MI, BURREL M., et al. - Chemoembolization of hepatocellular carcinoma with drug eluting beads : efficacy and doxorubicin pharmacokinetics. J Hepatol 2007, 46, 474-481. (Pubitemid 46201723)
11. [11] MORNEX F., GIRARD N., BEZIAT C. et al. - Feasibility and efficacy of high-dose-threedimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carci-noma non - eiligible for curative therapies-mature results of the French-phase IIRTF-1 trial. Int J Radiat Oncol Biol Phys 2006, 66, 1152-1158 (Pubitemid 44740208)
12. [12] EL-SERAG HB, RUDOPH KL. - Hepatocellular carcinoma : epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132, 2557-2576. (Pubitemid 46890874)
13. [13] THOMAS MB, CHADHA R., GLOVER K. et al. - Phase II study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007, 110, 1059-1067. (Pubitemid 47312872)
14. [14] PANG R., POON RT. - Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006, 242, 151-167. (Pubitemid 44485315)
15. SCHWARTZ JD, SCHWARTZ M., LEHRER D., et al.- Bevacizumab in unresectable hepatocellular carcinoma for patients without metastasis and without invasion of the portal vein. J. Clin. Oncol. 2006, 24 Suppl (18S), 4144.
16. MALKA D., DROMAIN C., FARACE F., et al. - Bevacizumab in patients with advanced hepato-celluar carcinoma : preliminary results of a phase II study with circulating endothelial cell monitoring. J. Clin. Oncol. 2007, 25 Suppl (18S), 4570.
17. [17] ZHU AX, BLASZKOWSKY L., RYAN D., et al. - Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol.2006, 24, 1898-1903. (Pubitemid 46638989)
18. THOMAS MB, CHADHA R., IWASAKI M., et al. - The combination of bevacizumab and erlotinib shows a significant biological activity in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2007, 25 Suppl (18S), 4567.
19. [19] SEMELA D., PIGUET AC, KOLEV M., et al. - Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J. Hepatol. 2007, 46, 840-848. (Pubitemid 46529039)
20. Liu L., CAO Y., CHEN C., et al. - Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenenesis and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66, 11851-11858.
21. ABOU - ALFA GK, SCHWARTZ L, RICCI S, et al. - Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006, 24, 4293-4300.
22. ZHU AX, SAHANI DV, DI TOMASO E, et al. - A phase II study of sunatinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2007, Suppl (18S), 4637.
23. FAIVRE SJ, RAYMOND E., DOUILLARD J., et al. - Assessment of safety and drug - induced tumor necrosis with sunatinib in patients with unresectable hepatocellular carcinoma. J. Clin. Oncol. 2007, Suppl(18S), 3546.
24. LLOVET J., RICCI S., MAZZAFERRO V., et al. - Sorafenib improves survival in advanced hepatocellular carcinoma : results of a phase III randomized placebo-controlled trial (SHARP trial). J. Clin. Oncol. 2007, 25 Suppl (18S), LBA1.